Oral mucositis (OM) is a debilitating but common side effect of chemotherapy and radiation therapy in patients suffering from a wide spectrum of cancers.  In severe OM it is often necessary to discontinue life-saving cancer treatment.  IZN-6N4 is an oral topical treatment designed to prevent the development of OM and to provide an improved quality of life for the patient throughout his/her cancer treatment.

Izun’s recently completed Phase II trial demonstrated a reduction of OM and associated oral pain in cancer patients receiving chemotherapy and radiation therapy. In addition, and unexpectedly, maintenance of overall health and well-being of the treated population was demonstrated.

Izun is preparing for a Post Phase II meeting with the FDA.

Market size estimated at $500 million.